IL-1 and atherosclerosis: a murine twist to an evolving human story.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 22201674.
- Also identified by DOI 10.1172/JCI61163 and PMC identifier 3248309.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inflammation is a critical component of atherosclerosis. IL-1 is a classic proinflammatory cytokine that has been linked to atherosclerosis. A clinical trial has been launched in which an antibody specific for IL-1β is being studied for its effects on cardiovascular events in patients with atherosclerosis. In this issue of the JCI, Alexander et al. report that mice lacking the receptor for IL-1 unexpectedly have features of advanced atherosclerosis that suggest the atherosclerotic plaques may be less stable. These findings illustrate the complexity of inflammatory pathways in atherosclerosis and suggest the need for careful calibration of antiinflammatory approaches to atherosclerosis.
Medical subject headings
- Interleukin-1
- Plaque, Atherosclerotic